Developer docs
API playgroundTry for free, no card

Search company profiles

Cell One Partners

Full company profile

uuid000ljlo

Namestring
Cell One Partners
Legal namestring
Cell One Partners Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Cell One Partners Inc. is a privately held strategic consulting firm founded in 2018 by George S. Goldberger, operating since 2019, and headquartered in New York, USA. The firm provides advisory services exclusively to the cell and gene therapy (CGT) industry, supporting clients across clinical development, manufacturing strategy, regulatory pathway development, commercialization infrastructure, human capital, and contract management. Its service portfolio includes six core offerings: Clinical Development Consulting, Market and Science Assessment, Process Development & Manufacturing, Commercialization Infrastructure, Human Capital Management, and Contract Management Services. Delivery is structured around a 4-person leadership team, a core team of 28+ experts, and a network of strategic advisors sourced from senior operating roles at Novartis, GSK, Amgen, Roche, Lonza, and Kite Pharma, as well as former CDMO executives from PCT/Minaris and PharmaCell.

The business model is professional services consulting with tailored, project-based engagements; no public pricing is disclosed. Customer segments span CGT developers (startups and emerging companies), CGT service providers including CDMOs and viral vector manufacturers, and private equity firms seeking market diligence for acquisitions and roll-up strategies. Disclosed engagements include $500M and $1B-scale PE due diligence projects, FDA Complete Response Letter responses, GMP audits, and market analyses spanning CGT, CDMO, viral vector, and tools markets. The firm is founder-owned, with no institutional investors or parent company identified, and operates a distributed delivery model across North America, Europe, the Middle East, and Asia Pacific. In November 2025, Cell One Partners extended beyond pure advisory through a partnership with Conner Strong & Buckelew and Citadel Insurance to co-develop the Product Shortage PLUS Endorsement, a specialized insurance product addressing CGT supply-chain risk.

Short descriptiontext

Cell One Partners is a New York-based strategic consulting firm founded in 2018 that advises cell and gene therapy developers, CDMOs, and private equity firms on clinical, manufacturing, regulatory, and commercialization strategy via a 30+ expert bench.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy consulting, gene therapy advisory, commercialization strategy, biotech regulatory consulting, CDMO due diligence
Industry2 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAJ
Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Management Consulting Services54161
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Biotechnology Consulting
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Consulting Services
TypeProfessional Services
Description

Professional consulting services provided to cell and gene therapy companies, including clinical development planning, manufacturing strategy, regulatory pathway development, market assessment, and due diligence support. Services are tailored to client needs through flexible engagement structures.

cellonepartners.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cell One Partners is a strategic consulting firm that helps cell and gene therapy (CGT) companies advance from laboratory to clinic to commercialization through tailored advisory engagements. Its offerings span clinical development planning, market and pipeline assessment, process development and manufacturing strategy, commercialization infrastructure setup, human capital management, and contract management services for emerging clients. Each engagement is staffed by an experienced client team drawn from a network of more than 30 industry experts and former executives from major pharmaceutical, biotech, and CDMO organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Supported client in achieving FDA IND approval for gene therapy product within mandated timelines
+1 more record
Product overview1 text field

Cell One Partners is a strategic consulting firm for cell and gene therapy companies, not a software product company. The company offers a portfolio of consulting services organized around the commercialization pathway for advanced therapy medicinal products (ATMPs). Their service offerings include: Clinical Development Consulting (clinical plan development, assessment reports, bioprocessing, analytical development, closed and automated processing, cost of goods analysis), Market and Science Assessment (pipeline asset evaluation, in-licensing options), Process Development & Manufacturing (manufacturing platform development, CMO management, technology transfers, GMP manufacturing), Commercialization Infrastructure (supply chain development, facility setup, IT infrastructure, regulatory submission, market access), and Human Capital Management (HR strategies, talent acquisition, organizational development). The company also provides access to a network of strategic advisors and industry insiders. There is no unified software platform; rather, Cell One Partners delivers hands-on expert consulting engagements tailored to client needs throughout the development and commercialization continuum.

Product and service6 records
1Clinical Development Consulting
CategoryStrategic Consulting Services
Description

Strategic consulting support for cell and gene therapy companies covering clinical plan development, assessment reports, bioprocessing, analytical development, closed and automated processing, and cost of goods analysis. Targeted at CGT development companies needing expert guidance on clinical development strategy.

2Market and Science Assessment
CategoryStrategic Consulting Services
Description

Evaluation services for in-licensing of pipeline assets and market opportunity assessment within the cell and gene therapy industry. Designed for CGT companies and investors seeking expert market and pipeline analysis.

3Process Development & Manufacturing
CategoryStrategic Consulting Services
Description

Manufacturing strategy services for cell and gene therapy companies, including robust manufacturing platform development, CMO selection, contract negotiation, ongoing management, process development, technology transfers, and GMP manufacturing support. Targeted at CGT developers and CDMOs.

4Commercialization Infrastructure
CategoryStrategic Consulting Services
Description

Development and establishment of commercialization infrastructure for cell and gene therapy products, including supply chain development, facility setup and FDA inspection, IT infrastructure, logistics, regulatory submission, and market access approach including billing code strategies and pricing and reimbursement strategy. Intended for CGT developers advancing toward commercial launch.

5Human Capital Management
CategoryStrategic Consulting Services
Description

Implementation of human capital strategies for cell and gene therapy organizations, including HR due diligence with leadership team assessment, talent acquisition, organizational design and development, compensation and benefits plan design, and creation of a best-in-class culture. Targeted at CGT companies and investors requiring HR due diligence and organizational development support.

6Contract Management Services
CategoryStrategic Consulting Services
Description

Comprehensive contract management services for emerging cell and gene therapy clients, supporting the negotiation, administration, and ongoing management of contracts associated with clinical development, manufacturing, and commercialization. Targeted at emerging CGT companies that need expert contract support alongside broader commercialization engagements.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Cell One Partners collaborated with Conner Strong & Buckelew to develop the Product Shortage PLUS Endorsement insurance solution for cell and gene therapy product shortages. This coverage addresses risks related to patient claims, operational failures, legal defense, and compliance in clinical trials, helping companies mitigate risks associated with complex supply chain and treatment delivery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

The Product Shortage PLUS Endorsement is offered through Citadel Insurance's BioPro program, developed in collaboration with Cell One Partners to address risks in the cell and gene therapy industry.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cell One Partners partners with AES for designing cleanroom facilities for cell and gene therapy companies.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Trinity Partners
TypeDirect peer
Description

Strategic consulting firm dedicated to life sciences, advising biopharmaceutical clients on strategy, pricing, and commercialization — directly comparable to Cell One Partners' biotech strategy and commercialization advisory offering.

TypeDirect peer
Description

Strategy consulting firm focused exclusively on healthcare and biotechnology, providing commercial, pipeline, and market access strategy to biopharma and medtech clients across all therapeutic areas, including advanced therapies.

TypeDirect peer
Description

Biopharmaceutical strategy consulting firm advising global pharma and biotech on commercial strategy, pricing, and market access — directly comparable in business model and target client base.

TypeDirect peer
Description

Biotech and pharma consulting firm (formerly including Defined Health and other life-sciences consultancies) providing strategic advisory, HEOR, and medical communications to biopharma, with overlap in advanced therapy strategy.

TypeDirect peer
Description

Life sciences-focused advisory firm providing strategic counsel and capital markets advisory to medtech, biotech, and digital health companies — comparable boutique peer in life-sciences strategy advisory.

TypeBroad incumbent
Description

Large global life-sciences services and consulting firm serving pharma, biotech, and medtech across R&D, clinical, and commercial; competes for high-end biopharma strategy mandates with much broader portfolio.

TypeBroad incumbent
Description

Biopharmaceutical services organization with a dedicated consulting practice covering R&D, medical, and commercial strategy for pharma/biotech — broader incumbent overlapping in CGT commercialization advisory.

TypeBroad incumbent
Description

Global management consulting firm with a Life Sciences practice providing strategy, litigation, and economic advisory to biopharmaceutical clients; broader incumbent with adjacent offerings.

TypeBroad incumbent
Description

Top-tier global strategy consultancy with a dedicated Life Sciences practice advising biopharma on corporate strategy, commercial, and operations — broader incumbent at the high end of strategic advisory.

TypeBroad incumbent
Description

Global management consultancy with a large Biopharma practice covering R&D, manufacturing, and commercial strategy for pharma and biotech, including advanced therapies — broadest-scale incumbent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cell One Partners

Biotechnology Consultingcellonepartners.com

Cell One Partners is a New York-based strategic consulting firm founded in 2018 that advises cell and gene therapy developers, CDMOs, and private equity firms on clinical, manufacturing, regulatory, and commercialization strategy via a 30+ expert bench.

What Cell One Partners does

Cell One Partners Inc. is a privately held strategic consulting firm founded in 2018 by George S. Goldberger, operating since 2019, and headquartered in New York, USA. The firm provides advisory services exclusively to the cell and gene therapy (CGT) industry, supporting clients across clinical development, manufacturing strategy, regulatory pathway development, commercialization infrastructure, human capital, and contract management. Its service portfolio includes six core offerings: Clinical Development Consulting, Market and Science Assessment, Process Development & Manufacturing, Commercialization Infrastructure, Human Capital Management, and Contract Management Services. Delivery is structured around a 4-person leadership team, a core team of 28+ experts, and a network of strategic advisors sourced from senior operating roles at Novartis, GSK, Amgen, Roche, Lonza, and Kite Pharma, as well as former CDMO executives from PCT/Minaris and PharmaCell.

The business model is professional services consulting with tailored, project-based engagements; no public pricing is disclosed. Customer segments span CGT developers (startups and emerging companies), CGT service providers including CDMOs and viral vector manufacturers, and private equity firms seeking market diligence for acquisitions and roll-up strategies. Disclosed engagements include $500M and $1B-scale PE due diligence projects, FDA Complete Response Letter responses, GMP audits, and market analyses spanning CGT, CDMO, viral vector, and tools markets. The firm is founder-owned, with no institutional investors or parent company identified, and operates a distributed delivery model across North America, Europe, the Middle East, and Asia Pacific. In November 2025, Cell One Partners extended beyond pure advisory through a partnership with Conner Strong & Buckelew and Citadel Insurance to co-develop the Product Shortage PLUS Endorsement, a specialized insurance product addressing CGT supply-chain risk.

Cell One Partners firmographics

Firmographics
Name
Cell One Partners
Legal name
Cell One Partners Inc.
Website
https://cellonepartners.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Cell One Partners is a New York-based strategic consulting firm founded in 2018 that advises cell and gene therapy developers, CDMOs, and private equity firms on clinical, manufacturing, regulatory, and commercialization strategy via a 30+ expert bench.
Ownership category
akta.pro rank

Cell One Partners industry classification

Industry
Product category
Biotechnology Consulting
NAICS
Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAJ
Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy consulting
  • Gene therapy advisory
  • Commercialization strategy
  • Biotech regulatory consulting
  • CDMO due diligence

Where Cell One Partners is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cell One Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Strategic Consulting Services: Professional consulting services provided to cell and gene therapy companies, including clinical development planning, manufacturing strategy, regulatory pathway development, market assessment, and due diligence support. Services are tailored to client needs through flexible engagement structures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cell One Partners product offering

Product offering

Core offering

Cell One Partners is a strategic consulting firm that helps cell and gene therapy (CGT) companies advance from laboratory to clinic to commercialization through tailored advisory engagements. Its offerings span clinical development planning, market and pipeline assessment, process development and manufacturing strategy, commercialization infrastructure setup, human capital management, and contract management services for emerging clients. Each engagement is staffed by an experienced client team drawn from a network of more than 30 industry experts and former executives from major pharmaceutical, biotech, and CDMO organizations.

Product overview

Cell One Partners is a strategic consulting firm for cell and gene therapy companies, not a software product company. The company offers a portfolio of consulting services organized around the commercialization pathway for advanced therapy medicinal products (ATMPs). Their service offerings include: Clinical Development Consulting (clinical plan development, assessment reports, bioprocessing, analytical development, closed and automated processing, cost of goods analysis), Market and Science Assessment (pipeline asset evaluation, in-licensing options), Process Development & Manufacturing (manufacturing platform development, CMO management, technology transfers, GMP manufacturing), Commercialization Infrastructure (supply chain development, facility setup, IT infrastructure, regulatory submission, market access), and Human Capital Management (HR strategies, talent acquisition, organizational development). The company also provides access to a network of strategic advisors and industry insiders. There is no unified software platform; rather, Cell One Partners delivers hands-on expert consulting engagements tailored to client needs throughout the development and commercialization continuum.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Development Consulting Strategic consulting support for cell and gene therapy companies covering clinical plan development, assessment reports, bioprocessing, analytical development, closed and automated processing, and cost of goods analysis. Targeted at CGT development companies needing expert guidance on clinical development strategy.
  • Market and Science Assessment Evaluation services for in-licensing of pipeline assets and market opportunity assessment within the cell and gene therapy industry. Designed for CGT companies and investors seeking expert market and pipeline analysis.
  • Process Development & Manufacturing Manufacturing strategy services for cell and gene therapy companies, including robust manufacturing platform development, CMO selection, contract negotiation, ongoing management, process development, technology transfers, and GMP manufacturing support. Targeted at CGT developers and CDMOs.
  • Commercialization Infrastructure Development and establishment of commercialization infrastructure for cell and gene therapy products, including supply chain development, facility setup and FDA inspection, IT infrastructure, logistics, regulatory submission, and market access approach including billing code strategies and pricing and reimbursement strategy. Intended for CGT developers advancing toward commercial launch.
  • Human Capital Management Implementation of human capital strategies for cell and gene therapy organizations, including HR due diligence with leadership team assessment, talent acquisition, organizational design and development, compensation and benefits plan design, and creation of a best-in-class culture. Targeted at CGT companies and investors requiring HR due diligence and organizational development support.
  • Contract Management Services Comprehensive contract management services for emerging cell and gene therapy clients, supporting the negotiation, administration, and ongoing management of contracts associated with clinical development, manufacturing, and commercialization. Targeted at emerging CGT companies that need expert contract support alongside broader commercialization engagements.

Quantifiable outcome

  • Supported client in achieving FDA IND approval for gene therapy product within mandated timelines
  • +1 more outcomes

Companies that use Cell One Partners

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Cell One Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cell One Partners partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Conner Strong & BuckelewcoreStrategic or Co-development Partner · 3 November 2025Cell One Partners collaborated with Conner Strong & Buckelew to develop the Product Shortage PLUS Endorsement insurance solution for cell and gene therapy product shortages. This coverage addresses risks related to patient claims, operational failures, legal defense, and compliance in clinical trials, helping companies mitigate risks associated with complex supply chain and treatment delivery.
  • Citadel Insurance (BioPro program)coreStrategic or Co-development Partner · 3 November 2025The Product Shortage PLUS Endorsement is offered through Citadel Insurance's BioPro program, developed in collaboration with Cell One Partners to address risks in the cell and gene therapy industry.
  • AES (Advanced Equipment Services)minorStrategic or Co-development PartnerCell One Partners partners with AES for designing cleanroom facilities for cell and gene therapy companies.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Cell One Partners competitors and assessment

Company assessment

Direct peers

  • Trinity Partners: Strategic consulting firm dedicated to life sciences, advising biopharmaceutical clients on strategy, pricing, and commercialization — directly comparable to Cell One Partners' biotech strategy and commercialization advisory offering.
  • Health Advances: Strategy consulting firm focused exclusively on healthcare and biotechnology, providing commercial, pipeline, and market access strategy to biopharma and medtech clients across all therapeutic areas, including advanced therapies.
  • Putnam Associates: Biopharmaceutical strategy consulting firm advising global pharma and biotech on commercial strategy, pricing, and market access — directly comparable in business model and target client base.
  • Lumanity: Biotech and pharma consulting firm (formerly including Defined Health and other life-sciences consultancies) providing strategic advisory, HEOR, and medical communications to biopharma, with overlap in advanced therapy strategy.
  • Back Bay Life Science Advisors: Life sciences-focused advisory firm providing strategic counsel and capital markets advisory to medtech, biotech, and digital health companies — comparable boutique peer in life-sciences strategy advisory.

Broad incumbents

  • IQVIA (Consulting & Analytics): Large global life-sciences services and consulting firm serving pharma, biotech, and medtech across R&D, clinical, and commercial; competes for high-end biopharma strategy mandates with much broader portfolio.
  • Syneos Health Consulting: Biopharmaceutical services organization with a dedicated consulting practice covering R&D, medical, and commercial strategy for pharma/biotech — broader incumbent overlapping in CGT commercialization advisory.
  • Charles River Associates: Global management consulting firm with a Life Sciences practice providing strategy, litigation, and economic advisory to biopharmaceutical clients; broader incumbent with adjacent offerings.
  • Bain & Company (Life Sciences practice): Top-tier global strategy consultancy with a dedicated Life Sciences practice advising biopharma on corporate strategy, commercial, and operations — broader incumbent at the high end of strategic advisory.
  • McKinsey & Company (Biopharma practice): Global management consultancy with a large Biopharma practice covering R&D, manufacturing, and commercial strategy for pharma and biotech, including advanced therapies — broadest-scale incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cell One Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cell One Partners leadership team

Management profile

Number of profiles

Profiles4 records

Cell One Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cell One Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell One Partners

What does Cell One Partners do?

Cell One Partners is a strategic consulting firm that helps cell and gene therapy (CGT) companies advance from laboratory to clinic to commercialization through tailored advisory engagements. Its offerings span clinical development planning, market and pipeline assessment, process development and manufacturing strategy, commercialization infrastructure setup, human capital management, and contract management services for emerging clients. Each engagement is staffed by an experienced client team drawn from a network of more than 30 industry experts and former executives from major pharmaceutical, biotech, and CDMO organizations.

Is Cell One Partners a public or private company?

Cell One Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cell One Partners founded?

Cell One Partners was founded in 2018. It employs 11 to 50 people.

Where is Cell One Partners based?

Cell One Partners is headquartered in New York, United States, in the North America region.

How does Cell One Partners make money?

One revenue line is on record: strategic Consulting Services.

Who are Cell One Partners's main competitors?

Direct peers on record are Trinity Partners, Health Advances, Putnam Associates, Lumanity and Back Bay Life Science Advisors. Broad incumbents are IQVIA (Consulting & Analytics), Syneos Health Consulting, Charles River Associates, Bain & Company (Life Sciences practice) and McKinsey & Company (Biopharma practice).

Does Cell One Partners have an API?

No public API is recorded for Cell One Partners.

What industry is Cell One Partners in?

Cell One Partners's product category is Biotechnology Consulting. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAAABAJ, Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring). Its NAICS code is 54161 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales